MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells

Kamila Kitowska1*, Monika Gorska-Arcisz1, Dima Antoun1, Izabela Zarczynska1, Dominika Czaplinska1, Adrian Szczepaniak1, Andrzej C. Skladanowski1, Maciej Wieczorek2, Aleksandra Stanczak2, Monika Skupinska2 and Rafał Sadej1*

1 Department of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland, 2 Innovative Drugs R&D Department, Celon Pharma, Lomianki/Kiełpin, Poland

Deregulation of fibroblast growth factor receptors (FGFRs) signaling, as a result of FGFR amplification, chromosomal translocation, or mutations, is involved in both initiation and progression of a wide range of human cancers. Clinical data demonstrating the dependence of cancer cells on FGFRs signaling clearly indicate these receptors as the molecular targets of anti-cancer therapies. Despite the increasing number of tyrosine kinase inhibitors (TKIs) being investigated in clinical trials, acquired resistance to these drugs poses a serious therapeutic problem. In this study, we focused on a novel pan-FGFR inhibitor—CPL304110, currently being investigated in phase I clinical trials in adults with advanced solid malignancies. We analyzed the sensitivity of 17 cell lines derived from cancers with aberrant FGFR signaling, i.e. non-small cell lung cancer, gastric and bladder cancer to CPL304110. In order to explore the mechanism of acquired resistance to this FGFR inhibitor, we developed from sensitive cell lines their variants resistant to CPL304110. Herein, for the first time we revealed that the process of acquired resistance to the novel FGFR inhibitor was associated with increased expression of MET in lung, gastric, and bladder cancer cells. Overexpression of MET in NCI-H1703, SNU-16, RT-112 cells as well as treatment with HGF resulted in the impaired response to inhibition of FGFR activity. Moreover, we demonstrated that cells with acquired resistance to FGFR inhibitor as well as cells overexpressing MET displayed enhanced migratory abilities what was accompanied with increased levels of Pyk2 expression. Importantly, inhibition of both MET and Pyk2 activity restored sensitivity to FGFR inhibition in these cells. Our results demonstrate that the HGF/MET-Pyk2 signaling axis confers resistance to the novel FGFR inhibitor, and this mechanism is common for lung, gastric, and bladder cancer cells. Our study suggests that targeting of MET/Pyk2 could be an approach to overcome resistance to FGFR inhibition.

Keywords: FGFR, MET, Pyk2, acquired resistance, cancer
INTRODUCTION

The fibroblast growth factor receptor family comprises four (FGFR1-4) receptor tyrosine kinases (RTKs) involved in the regulation of many downstream effectors including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/Akt, or STATs, that are crucial for cell proliferation, survival, differentiation, and motility (1, 2). Taking into account the significance of these processes in tumorigenesis, aberrant FGFR signaling has been shown to play an essential role in cancer cell survival, proliferation, as well as tumor neoangiogenesis (3). Amplification of FGFR genes, chromosomal translocation, and gain-of-function mutations could result either in constitutive ligand-independent FGFR activation or enhanced ligand-dependent signaling, whereby, both processes have been demonstrated to be involved in initiation and progression of a wide range of human cancers (4–6). FGFR1 amplification has been identified in 10–20% of patients with non-small cell lung cancer whereas 4–10% of primary gastric cancers and approximately 75% of bladder cancers harbor FGFR2 amplification and FGFR3 mutations, respectively (7–10). These clinical data demonstrate the dependence of cancer cells on FGFR signaling and suggest an urgent requirement of molecular therapies targeting FGFR activity. Several tyrosine kinase inhibitors (TKIs) of FGFRs are currently being investigated in anticancer clinical trials (NCT03344536, NCT02465060, NCT02052778, NCT02393248). However, most small-molecule inhibitors display either limited selectivity for FGFR or significant activity against other RTKs, such as vascular endothelial growth factor (VEGFR) or platelet-derived growth factor (PDGFR) (11–13). Therefore, the discovery of FGFR inhibitors has become a rapidly growing research area (14). According to the mechanism of inhibitor activity, selective FGFR inhibitors either belong to the group of molecules that reversibly occupy the ATP-binding pocket or the group that irreversibly bind covalently to a specific cysteine residue within the receptor kinase domain. As a result of selective FGFR inhibitors’ action phosphorylation of FGFRs and their direct downstream targets, i.e. Fibroblast Growth Factor Receptor Substrate 2-α (FRS2-α) and phospholipase C-γ-1 (PLC-γ-1), is reduced. Despite outstanding progress in the field of targeted therapies and the increasing number of selective inhibitors in clinical trials, adverse effects and development of resistance to applied drugs continue to be serious clinical issues. Only several preclinical and clinical studies investigated the mechanism of acquired resistance to FGFR inhibitors. Secretome screening studies revealed that in multiple cancer cell lines initially dependent on FGFR signaling, activation of the respective alternative kinase could rescue growth upon FGFR inhibitor treatment (15). In vitro studies on lung cancer cells showed that decrease in phosphorylation level of extracellular signal-regulated kinase (ERK) 1/2 and Akt mediated by FGFR inhibition with AZD4547 or BAY1163877 was hampered by MET activation (16). Research performed in bladder cancer cell lines revealed a rapid induction of HER2 and HER3 in cells treated with the FGFR inhibitor, BGJ398, thus suggesting that a switch from FGFR- to HER2/3-dependency can compensate FGFR inhibition (17). Protein kinase C (PKC)-mediated phosphorylation of GSK-3β which led to activation of downstream pro-survival proteins was identified as a mechanism of resistance to AZD4547 in gastric cancer cell lines (18). These data indicate the complexity of acquired resistance to FGFR inhibition and pose a significant challenge to identify common pathways responsible for resistance in various cancers.

In this study, we focused on a novel pan-FGFR inhibitor, CPL304110 (Celcon Pharma, Poland), which currently has been investigated in phase I clinical trial in adults with advanced solid malignancies (NCT04149691) (19). We analyzed sensitivity to CPL304110 in a panel of cell lines derived from cancers displaying aberrant FGFR signaling, i.e. non-small cell lung cancer, gastric and bladder cancers (20–26). We developed cell line variants resistant to CPL304110 in order to explore a mechanism of acquired resistance. We found that the process was associated with increased expression of MET in lung, bladder, and gastric cancer cells. In addition, ectopic overexpression of MET resulted in impaired cell response to FGFR inhibition. Both, CPL304110-resistant and MET-overexpressing cells were also found to have increased level of Pyk2. Inhibition of MET and Pyk2 restored sensitivity of resistant cells to FGFR inhibition. These results suggest that the MET/Pyk2 axis induces acquired resistance to FGFR inhibition in cancer cells.

MATERIALS AND METHODS

Cell Lines, Antibodies, and Reagents

DMS114, NCI-H1581, NCI-H1703, NCI-H2170, NCI-H520, SNU-1, SNU-5, SNU-16, SW780, and AGS cell lines were obtained from ATCC. 639V, T24, KATO-III, UM-UC-3, UM-UC-14, UM-UC-16, and RT-112 cell lines were obtained from ECACC. SW780 and 639V cells were routinely maintained in DMEM; NCI-H1581 cells in DMEM/F12; UM-UC-3, UM-UC-14, UM-UC-16, and RT-112 cells in EEM; SNU-5 cells in IMDM; DMS114 cells in Waymouth’s MB752/1. NCI-H1703, NCI-H2170, NCI-H520, SNU-1, SNU-16, AGS, T24, and KATO-III cells were maintained in RPMI 1640 medium. All culture media contained 10% FBS and penicillin/streptomycin (100 U/ml/100 μg/ml). Cells were grown at 37°C in a humidified atmosphere of 5% CO2, passed for a maximum of 3–4 months post resuscitation, and regularly tested for mycoplasma contamination. All culture media and corresponding supplements were purchased from Sigma-Aldrich or Biowest. The following antibodies were obtained from Santa Cruz Biotechnology: anti-EGFR (sc-373746), anti-FAK (sc-271116), anti-FGFR1 (sc-57132), anti-FGFR3 (sc-13121), anti-FGFR4 (sc-136988), anti-FRS2-α (sc-17841), anti-Paxillin (sc-365379). The antibody against β-actin (A5316) was obtained from Sigma-Aldrich. All the remaining antibodies were from Cell Signaling Technology: anti-Akt-Tyr473 (#9271) anti-Akt (#92720), anti-EGFR-Tyr1068 (#3777), anti-Erk1/2-Thr202/Tyr204 (#4377), anti-Erk1/2 (#9102), anti-FAK-Tyr397 (#3283), anti-FGFR1-Tyr653/654 (#3471), anti-FGFR2 (#23328), anti-FRS2-α-Tyr196 (#3864), anti-FRS2-α-Tyr436 (#3861), anti-HER2 (#4290), anti-HER2-Tyr148 (#2247), anti-HER3 (#4754), anti-HER3-Tyr1289 (#4791), anti-MET (#4560), anti-MET-Tyr1235/1236 (#3077), anti-PLC-γ-1-Tyr783 (#2821), anti-PLC-γ-1 (#2822), anti-Pyk2-Tyr402 (#3291), anti-Pyk2 (#3292), anti-
Paxillin-Tyr118 (#69363), and anti-Src-Tyr416 (#2101), anti-Src (#2105). Hepatocyte growth factor was purchased from PeproTech. Inhibitors: CPL304110 (WO/2014/141015) was provided by Celon Pharma, Poland; capmatinib was purchased from Selleckchem and PF431396 was purchased from Sigma-Aldrich.

**Cell Proliferation Assay**

Cell viability was estimated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Cells were seeded in 96-well plates in triplicates and on the following day treated with DMSO or increasing concentrations of CPL304110 for 48 and 96 h. MTT stock solution was added to each well so that the final concentration of MTT in the medium was 0.5 mg/ml. After 2 h of incubation at 37°C, the medium was discarded and MTT formazan was dissolved in DMSO. The absorbance was measured at 590 nm using a microplate reader.

**Generation of CPL304110-Resistant Cell Lines**

To develop resistance to the FGFR inhibitor CPL304110, NCI-H1703, SNU-16, RT-112 cell lines were gradually exposed to increasing concentrations of CPL304110 with starting dose of the inhibitor at 5 nM. Cells were maintained in medium with the inhibitor which was replaced every 72 h. When the growth kinetics of treated cells were similar to wild-type counterpart cell lines, the concentration of CPL304110 was increased until a final concentration of 5 μM was achieved. After 4–6 months of such culture, resistant cells were established and termed accordingly NCI-H1703R, SNU-16R, and RT-112R.

**Stable Overexpression of MET**

NCI-H1703/MET†, SNU-16/MET†, and RT-112/MET† cell lines were generated with a retroviral system based on pBABE-puro TRP-Met vector (Addgene, #10902) (29). To generate cells with stable expression, the plasmids were transfected into HEK293T packaging cells with TurboFect™ (Invitrogen). After 24 h, medium containing virus particles was collected and used to infect host cells in the presence of 5 μg/ml polybrene. Selection with 5 μg/ml puromycin (Sigma-Aldrich) was conducted to obtain resistant cells with stable overexpression of MET. This was confirmed by western blotting.

**Western Blotting Analysis**

For western blot analysis, cells were harvested at 60–70% confluency and lysed with Laemmlli buffer (2× concentrated) with 2 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 5 mM EGTA, 1 mM EDTA, 2 mM Na₂P₂O₇, 5 mM NaF, and 5 mM Na₂VO₄. Samples with equal amounts of protein were loaded per well, resolved in SDS-PAGE and then transferred onto nitrocellulose membrane. The membranes were blocked for 1 h in 5% skimmed milk and probed with specific primary antibodies at 4°C. Appropriate secondary Alexa Fluoro®-conjugated antibodies (680 or 790 nm) (Jackson ImmunoResearch, #111-625-144, #715-655-150) and Odyssey® CLx imaging system (LI-COR® Biosciences) were used to detect protein bands.

**Statistical Analysis**

Data are expressed as mean ± SD from at least three independent experiments. Comparative data were analyzed with the unpaired Student’s t-test using the Statistica™ software (v.10; StatSoft®, Inc., Tulsa, OK, USA). Two-sided p ≤ 0.05 was considered to indicate a statistically significant difference.
(with IC$_{50}$ ≤1 µM), whereas growth of DMS114, NCI-H2170, NCI-H520, SNU-1, SNU-5, AGS, UM-UC-3, UM-UC-16, 639V, and T24 cells was not significantly affected (Figures 1A, S1A–C, and Table S1). As amplification/overexpression of FGFR1, FGFR2, and FGFR3 contributes to progression of lung, gastric, and bladder cancers, respectively, we verified their level of expression in all analyzed cell lines (4, 24, 31–35). This indicated that CPL304110 exhibits higher potency in the cells expressing elevated level of FGFRs (Figure S1D). As FGFR1 is overexpressed in approx. 20% of non-small cell lung cancer (4), the NCI-H1703 non-small cell lung cancer cell line was used for further studies. As a model of gastric and bladder cancers, we respectively used SNU-16 and RT-112 cells, shown to be highly sensitive to FGFR inhibition. The efficacy of CPL304110 in these cells was compared to that of AZD4547, another well-studied FGFR inhibitor. CPL304110 inhibited cell proliferation with a higher potency in comparison to AZD4547, i.e. CPL304110 IC$_{50}$ 1 µM; 0.04 µM and 0.15 µM vs AZD4547 IC$_{50}$; 3.4 µM; 0.06 µM and 0.8 µM in NCI-H1703, SNU-16 and RT-112 cells, respectively (Supplementary Data, Table S2). The impact of CPL304110 on cell growth was additionally evaluated in 3D cultures in Matrigel® (Figure 1B). Since NCI-H1703 cells do not form typical spheroids in 3D Matrigel® and exhibit highly invasive growth, quantitative analysis of the inhibitory effect of CPL304110 was therefore not possible. However, a negative effect of the drug on cell growth was apparent in all tested cell lines. Moreover, we demonstrated a negative effect of CPL304110 on phosphorylation of FGFR and its direct downstream effectors FRS2-α, PLC-γ-1 as well as Akt, Erk1/2 in NCI-H1703, SNU-16, RT-112 cells (Figure S1E).

**Development of Resistance to FGFR Inhibitor**

In order to investigate the mechanisms of acquired resistance to FGFR inhibition, CPL304110-resistant variants of NCI-H1703, SNU-16, and RT-112 cells were developed. Cells were cultured for up to 6 months in the presence of gradually increasing concentrations of CPL304110 in order to develop acquired resistance. Subsequently, sensitivity to CPL304110 was compared with the corresponding parental cell lines. Analysis of 3D growth revealed that NCI-H1703R, SNU-16R, and RT-112R cells demonstrated significantly impaired response to CPL304110 (Figures 2A, S2A). This was further confirmed by analysis of cell proliferation (Figure S2B). In order to determine the mechanism of resistance to FGFR inhibition, we confirmed that the activity of FGFR and its downstream effectors, i.e. Fibroblast Growth Factor Receptor Substrate 2-α (FRS2-α) and phospholipase C-γ-1 (PLC-γ-1), was dramatically impaired.

---

**FIGURE 1 | Anti-proliferative effect of CPL304110.** (A) NCI-H1703, SNU-16, and RT-112 were exposed to the indicated concentrations of the FGFR inhibitor, CPL304110, for 48 and 96 h followed by assessment of cell viability using the MTT assay. Data are expressed as mean ± SD, n = 3. (B) Cells were grown in 3D Matrigel® for 14 days in the presence of CPL304110. Representative pictures were taken, colonies were measured and statistically analyzed with ImageJ. Scale bar represents 100 µm. Data are expressed as mean ± SD. **p ≤ 0.01, ***p ≤ 0.001, n = 3.
in NCI-H1703R, SNU-16R, and RT-112R cells when compared to the corresponding parental cell lines (Figure 2B). Since resistance to FGFR inhibition could be initiated by activation of alternative RTKs signaling (15, 36), the expression and activity of EGFR, HER2, HER3, and MET was analyzed in the resistant cell lines (Figure 2C). Although there were minor discrepancies in the expression or activity of various RTKs, upregulated MET expression (at both mRNA and protein level) as well as activity was observed in all analyzed resistant cell lines (Figures 2C, S2C). As a result of this, MET was considered in further studies as a potential inducer of resistance to CPL304110.

**MET Activation Mediates Resistance to FGFR Inhibition**

Since we observed that MET phosphorylation was increased in the resistant cell lines, we investigated further whether incubation of the parental cell lines, NCI-H1703, SNU-16, and RT-112 with HGF could counteract CPL304110-dependent inhibition of growth. We observed that although HGF did not significantly promote 3D cell growth, it exerted a strong protective effect against CPL304110 in all tested cell lines (Figures 3A, S3A). In contrast, inhibition of MET activity with
capmatinib (highly sensitive MET inhibitor, FDA approved for NSCLC treatment) restored sensitivity of NCI-H1703R, SNU-16R, and RT-112R cells to CPL304110 (Figures 3B, S3B). Moreover, stable MET overexpression in NCI-H1703, SNU-16, and RT-112 cells (Figure 4A) resulted in strongly impaired sensitivity of these cells to FGFR inhibitor (Figures 4B, C). Strikingly, when the combination of CPL304110 and capmatinib was applied in both 3D growth and classical 2D proliferation assays, growth for NCI-H1703/MET↑, SNU-16/MET↑, and RT-112/MET↑ cells was dramatically affected.

Pyk2 Mediates Migratory Abilities of Cells Resistant to FGFR Inhibitor

The observed results herein indicated MET involvement in resistance of lung, bladder, and gastric cancer cells to CPL304110. MET activity regulates not only proliferation but also cancer cell motility, invasion, and eventual metastasis (37, 38). Therefore, it was investigated whether MET-dependent resistance to CPL304110 is associated with changes in the migratory abilities of cells. This was verified in transwell migratory assay, which revealed enhanced migration in NCI-H1703R and NCI-H1703/MET↑ cells (2.34-fold and 2.31-fold increase, respectively), as well as in RT-112R and RT-112/MET↑ cells (1.83-fold and 1.67-fold increase, respectively) (Figure 5A). Next, we investigated the activity of proteins involved in the regulation of focal adhesions (i.e. Pyk2, FAK, and Src), previously reported to be MET-regulated (39). We explored this in parental and FGFR inhibitor-resistant NCI-H1703, SNU-16, and RT-112 cells. We found that neither FAK nor Src displayed changes in their activity following acquired resistance to CPL304110 (Figure 5B), however, upregulated phosphorylation of Pyk2, a non-receptor tyrosine kinase that acts as an integrator of survival, adhesion, and migration, was found in NCI-H1703R, SNU-16R, and RT-112R and in cells with ectopic MET expression (Figure S4A) (40). Moreover, MET inhibition led to decrease in Pyk2 phosphorylation in these cells (Figure S4B). Next, it was investigated whether inhibition of Pyk2 could deteriorate migratory potential of CPL304110-resistant and MET-overexpressing cells, as we could observe that Pyk2 inhibition resulted in decrease of FAK and paxillin phosphorylation in CPL304110 resistant cells (Figure S4C). Application of PF431396-Pyk2 inhibitor resulted in significantly decreased migration of NCI-H1703R (165.94 vs 57.49%), RT-112R (179.86 vs 88.26%), NCI-H1703/MET↑ (133.55 vs 32.62%), and RT-112/MET↑ (171.98 vs 102.70%) (Figure 5C).

Pyk2 Mediates MET-Dependent Resistance to FGFR Inhibition

To further elucidate the functional relevance of Pyk2 in CPL304110-resistance, NCI-H1703/MET↑, SNU-16/MET↑, and RT-112/MET↑ cells were treated with Pyk2 inhibitor (PF431396). Although inhibition of Pyk2 had modest effect on growth of cells overexpressing MET, it re-sensitized them to the FGFR inhibitor (Figures 6A, S5A). Similar effects were observed in resistant cell variants (Figure S5B). It is well known that Pyk2 links numerous signaling pathways and that its activity is induced by heregulin (HRG), epidermal growth factor (EGF), or transforming growth factor-β (TGF-β) (41, 42). Thus, it was elucidated whether HGF/MET→Pyk2 signaling confers resistance to CPL304110. We
observed that inhibition of Pyk2 abrogated protective effect of HGF for CPL304110-treated NCI-H1703, SNU-16, and RT-112 cells (Figures 6B, S6). Collectively, these observations indicate that HGF/MET signaling triggers a Pyk2-mediated mechanism of resistance to FGFR inhibitor that appears to be common in lung, gastric, and bladder cancer cells (Figure 6C).

**DISCUSSION**

Deregulated FGFR signaling as a result of FGFR gene amplification, mutations, or fusions has been identified in various malignancies including lung, gastric, and bladder cancers (43). This provided a strong rationale for development of anti-FGFR therapeutic agents classified as non-selective and selective FGFR inhibitors. Non-selective FGFR TKIs, e.g., nintedanib, lenvatinib, dovitinib, lucitanib, exert a series of toxic effects due to poor target selectivity (13, 44–46). Second generation selective FGFR TKIs have been developed to avoid off-target effects; however, only a few of them entered clinical trials. Studies for AZD4547 and BGJ389 revealed that patients with FGFR1 amplification (non-small cell lung cancer) or bearing FGFR3 mutations (bladder cancer) displayed a partial response to the therapy (47, 48). Thus far, erdafitinib and pemigatinib are the first FDA-approved FGFR selective inhibitors for treating urothelial cancer with FGFR2 or FGFR3 alterations, and cholangiocarcinoma with FGFR2 fusions and rearrangements, respectively (49–51). Despite the increasing number of selective FGFR inhibitors, poor clinical response and acquired resistance to these drugs remain the main clinical issue (52, 53).

In the present study, we provide preclinical data for a novel FGFR TKI, CPL304110, that has recently entered phase I of clinical trials in adults with advanced solid malignancies. Our in vitro data performed in a panel of 17 human cell lines derived from lung, gastric, bladder cancers showed that CPL304110 inhibits growth of cells displaying elevated FGFR expression with higher potency than AZD4547. Tudrej and colleagues also confirmed higher efficacy of CPL304110 in comparison to AZD4547 in ovarian cancer cells (54). In order to investigate the mechanism of acquired resistance to CPL304110, we generated resistant variants of lung, gastric, and bladder cancer cell lines. We observed that the activity of FGFRs and their direct downstream
Effectors, i.e. FRS2-α and PLC-γ-1 was abolished in resistant cells and that this was accompanied by upregulation of MET expression. Increased activity of MET has been previously reported to mediate resistance to EGFR inhibitors (e.g. osimertinib) in non-small cell lung cancer via EGFR-independent phosphorylation of HER3 and PI3K/Akt activation, providing a bypass pathway in the presence of an EGFR inhibitor (55). In our studies, the stable overexpression of MET in CPL304110 sensitive cells abolished a negative effect of the drug for cell growth, whereas inhibition of MET activity in resistant cells restored sensitivity to CPL304110. These results are in concordance with previously published data, demonstrating that resistance to FGFR inhibitors in FGFR1-amplified lung cancer cells can be acquired through MET activation (16, 56). Consistent with our results, HGF-mediated migration in small cell lung cancer cell lines with simultaneous Pyk2 phosphorylation on Tyr402 in response to HGF (58). Moreover, Verma and colleagues demonstrated that MET-mediated activation of Pyk2 contributes to metastasis of breast cancer (42, 59). Interestingly, Pyk2 is also considered as an independent prognostic factor for non-small cell lung cancer patients, as high expression and phosphorylation levels of Pyk2 were correlated with poor overall survival (60). Moreover, Pyk2-mediated induction of proliferation in both normal and tumor cells has been widely studied (61, 62) and involves ERK1/2, PI3K-Akt, Wnt/β-catenin activity (63–67).

In conclusion, our study indicates that MET-mediated activation of Pyk2 could confer resistance to CPL304110, a novel FGFR inhibitor and that the mechanism appears to be common in lung, gastric, and bladder cancer cell lines, thus suggesting that targeting of MET-Pyk2 axis could be a therapeutic strategy to overcome resistance to FGFR inhibitors. Further clinical activity evaluation of these pathways would be required to identify patients who are likely to develop resistance to the drug and would therefore benefit from combined therapy.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

KK planned and carried out the experiments and data curation, wrote and edited the manuscript, and prepared all figures. MG-A carried out the experiments and edited manuscript. DA, IZ, DC, and ASz carried out the experiments. MW, AS, and MS took part in funding acquisition, reviewed and made significant revisions of the manuscript, and guidance of chemical synthesis of CPL304110. ASk reviewed and made revisions of the manuscript. RS took part in funding acquisition, provided direction and guidance throughout the experimental process and preparation of this manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported within the “CELONKO” project (STRATEGMED2/266776/17/NCBR/2015), co-financed by the Polish National Center of Research and Development, and the pharmaceutical company CelonPharma S.A.
ACKNOWLEDGMENTS

pBabe-puro TPR-Met was a gift from Bob Weinberg (Addgene). We thank Dr. Eva McGrowder (The Institute of Cancer Research, London) for critical reading the manuscript.

REFERENCES

1. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res (2012) 18:1835–62. doi: 10.1158/1078-0432.CCR-11-0699
2. Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 4:215–66. doi: 10.1002/wdev.176
3. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2011) 149:121–30. doi: 10.1093/jb/mvq121
4. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 2:62ra93. doi: 10.1126/scitranslmed.3001451
5. Simon R, Richter J, Wagner U, Fijian A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res (2001) 61:4514–9.
6. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res (2001) 61:3541–3.
7. Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer (2015) 87:1–7. doi: 10.1016/j.lungcan.2014.11.009
8. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer (2014) 110:967–75. doi: 10.1038/bjc.2013.802
9. van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. FGFR1 dependency in squamous cell lung cancer. Gut (2012) 61:673–84. doi: 10.1136/gutjnl-2011-301839
10. Billerley C, Chopin D, Aubriot-Lorton MH, Ricold D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol (2001) 158:1955–6. doi: 10.1016/S0002-9440(01)66465-2
11. van Rhijn BW, Lurkin I, Radvanyi F, Kirlkes WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res (2001) 61:1265–8.
12. Cappellen D, De Oliveira C, Ricold D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 23:18–20. doi: 10.1038/12615
13. Dutt A, Ramos AH, Hammerman PS, Merel C, Cho J, Sharifinia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 6:e20351. doi: 10.1371/journal.pone.0020351
14. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2013) 31:731–7. doi: 10.1200/JCO.2012.43.8622
15. Tran TN, Selinger CI, Kohonen-Corijn M, McCaughan BC, Kennedy CW, O’Toole SA, et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer (2013) 81:462–7. doi: 10.1016/j.lungcan.2013.05.015
16. Mieszkowska M, Piascicka D, Potemski P, Debksa-Szmich S, Rychlowski M, Kordek R, et al. Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells. Transl Res (2019) 207:44–55. doi: 10.1016/j.trsl.2018.12.007
17. Turczyk L, Kitowska K, Mieczkowska M, Czapinski K, Piascika D, Piascicka D, et al. FGFR2-Driven Signaling Counteracts Tamofoxifen Effect on ERαPositive Breast Cancer Cells. Neoplasia (2017) 19:791–804. doi: 10.1016/j.neo.2017.07.006
18. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 37:1047–54. doi: 10.1038/ng1634
19. Sadej B, SKladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol (2012) 59:647–52. doi: 10.18388/abp.2012_2105
20. Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodriguez-Santiago B, Mendez-Pertuz M, Auer H, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics (2015) 16:403. doi: 10.1186/s12864-015-1450-3
21. Gust KM, McConkey DJ, Averey S, Hegarty PK, Qing J, Bondaruk J, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther (2013) 12:1245–54. doi: 10.1158/1535-7163.MCT-12-1150
22. Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, et al. FGFR3 translocations in bladder cancer: differential sensitivity to HS990 inhibition.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.633410/full#supplementary-material
based on drug metabolism. *Mol Cancer Res* (2014) 12:1042–54. doi: 10.1158/1541-7766.MCR-14-0004

34. Willummar SD, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. *Hum Mol Genet* (2012) 21:795–803. doi: 10.1093/hmg/ddq486

35. Grygielewicz P, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. *Gastric Cancer* (2016) 19:53–62. doi: 10.1007/s11012-014-0444-1

36. Adachi Y, Watanabe K, Kita K, Kotani H, Sato Y, et al. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. *Carcinogenesis* (2017) 38:1063–72. doi: 10.1093/carcin/bgw091

37. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenicity and epithelial-mesenchymal transition in hepatoacellular carcinoma via Akt and COX-2 pathways. *Clin Exp Metastasis* (2011) 28:271–31. doi: 10.1007/s10444-011-9404-x

38. Gu Y, Khan MGM, Bobbala D, Dubois C, Ramanathan S, Sauzier C, et al. Attenuation of MET-mediated migration and invasion in hepatoacellular carcinoma cells by SOCS1. *World J Gastroenterol* (2017) 23:6639–49. doi: 10.3748/wjg.v23.i36.6639

39. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. *Br J Cancer* (2007) 97:368–77. doi: 10.1038/sj.bjc.6603886

40. Shen T, Guo Q. Role of Pyk2 in Human Cancers. *Med Sci Monit* (2018) 24:8172–8182. doi: 10.12659/MSM.913479

41. Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, Keydar I, et al. RAFTK/Pyk2 tyrosine kinase mediates the association of p190RhoGAP with RasGAP and is involved in breast cancer cell invasion. *Oncogene* (2000) 19:1318–28. doi: 10.1038/sj.oanc.1203422

42. Verma N, Keinan O, Selitrennik M, Karn T, Filipitis M, Lev S. PYK2 sustains tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. *Oncotarget* (2015) 6:2009–22. doi: 10.18632/oncotarget.29887

43. Holden R, Welle T, Rajapakse K, Pond A, Coarfa C, Mo Q, et al. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. *Breast Cancer Res* (2015) 17:141. doi: 10.1186/s13058-015-0649-1

44. Tucler P, Olhava EJ, Zenbula-Nożyńska E, Kujawa KA, Cortez AJ, Fiszner-Kierzkowska A, et al. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVP8A. *Int J Mol Sci* (2018) 19(7):2080. doi: 10.3390/ijms19072080

45. Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. *J Hematol Oncol* (2019) 12:63. doi: 10.1186/s13045-019-0759-9

46. Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, et al. Mechanisms of Primary Drug Resistance in. *Clin Cancer Res* (2017) 23:5527–36. doi: 10.1158/1078-0432.CCR-17-0478

47. Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. *Mol Cancer* (2018) 17:45. doi: 10.1186/s12943-018-0796-y

48. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GL, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. *Clin Cancer Res* (2002) 8:620–7.

49. Verma N, Müller AK, Kothari C, Panatopolopoulou E, Kedan A, Selitrennik M, et al. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. *Cancer Res* (2017) 77:86–99. doi: 10.1158/0008-5472.CAN-16-1797

50. Kuang BH, Zhang MQ, Xu LH, Hu LJ, Wang HB, Zhao WF, et al. Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients’ overall survival. *Br J Cancer* (2013) 109:1252–63. doi: 10.1038/bjc.2013.439

51. Zhao T, Bao Y, Lu X, Ye Y, Gan X, Wang J, et al. Pyk2 promotes tumor progression in renal cell carcinoma. *Onco Lett* (2018) 16:5953–9. doi: 10.3892/ol.2018.9412

52. Guessous F, Yang Y, Johnson E, Marcinkiewicz L, Smith M, Zhang Y, et al. Cooperation between c-Met and focal adhesion kinase family members in medulloloblastoma and implications for therapy. *Mol Cancer Ther* (2012) 11:288–97. doi: 10.1158/1535-7163.MCT-11-0490

53. Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang W, Mishima Y, et al. Pyk2 promotes tumor progression in multiple myeloma. *Blood* (2014) 123:2675–86. doi: 10.1182/blood-2014-03-563981

54. Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. *Carcinogenesis* (2008) 29:2096–105. doi: 10.1093/carcin/bgn203

55. Perez J, Torres RA, Rocic P, Cismowski MJ, Weber DS, Darley-Usmar VM, et al. PYK2 signaling is required for PDGF-dependent vascular smooth muscle cell proliferation. *Am J Physiol Cell Physiol* (2011) 301:C242–51. doi: 10.1152/ajpcell.00351.2010

56. Liu S, Chen L, Xu Y. Significance of PYK2 level as a prognosis predictor in colon adenocarcinoma. *World J Gastroenterol* (2017) 23:5526–73. doi: 10.3748/wjg.v23.i36.5526

57. Mazzola CR, Siddiqui KM, Billia M, Chin J, Dovitinib to treat urothelial carcinoma. *Drugs Today (Barc)* (2019) 55:495–501. doi: 10.1388/dot.2019.55.8.3010573

58. Roubal K, Myint ZW, Kolesar JM. Erda. *Clin Exp Metastasis* (2017) 35:157. doi: 10.1200/jco.2016.67.2048

59. Hanna KS. Erdafitinib to treat urothelial carcinoma. *Drugs Today (Barc)* (2019) 55:495–501. doi: 10.1388/dot.2019.55.8.3010573

60. Roubal K, Myint ZW, Kolesar JM. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. *Am J Health Syst Pharm* (2020) 77:346–51. doi: 10.1093/ajhp/zzaa329

61. Hoy SM. Pemigatinib: First Approval. *Drugs* (2020) 80:923–9. doi: 10.1007/s40265-020-01330-y

62. Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, et al. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. *Oncotarget* (2015) 6:2009–22. doi: 10.18632/oncotarget.29887

63. Holdman R, Welte T, Rajapakse K, Pond A, Coarfa C, Mo Q, et al. Upregulation of EGFR signaling is correlated with tumor stroma remodeling.